Overview
NICE is unable to make a recommendation on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in people 12 years and over. This is because Roche did not provide a complete evidence submission.
Last reviewed: 07 January 2026
This guidance updates and replaces NICE technology appraisal guidance 644 on entrectinib for treating NTRK fusion-positive solid tumours, which was available through the Cancer Drugs Fund. People already having it will be able to continue until they and their healthcare professional decide when best to stop.
Next review: We will review this decision if the company decides to make a complete submission.